About HepaRegeniX
HepaRegeniX is a Healthcare company based in Tubingen (Germany) founded in 2017 by Lars Zender, Stefan Laufer, and Wolfgang Albrecht. Small molecule therapeutics for liver diseases are developed. HepaRegeniX has raised $62.15 million across 4 funding rounds from investors including Ascenion, Novoseeds and Wellington Partners Venture Capital. HepaRegeniX offers products and services including HRX-215. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its legal entity is HepaRegeniX GmbH.
Company details
HepaRegeniX was founded in 2017 in Tubingen, Germany, and operates in the biotechnology sector. Small molecule therapeutics are developed by the company, with a focus on inhibitors of Mitogen-Activated Protein Kinase Kinase 4 (MKK4). This target regulates liver regeneration, enabling hepatocyte recovery in acute and chronic liver conditions. Leadership includes co-founders Lars Zender, Stefan Laufer, and Wolfgang Albrecht, alongside Managing Director Birgit Jung.
- Headquarters Tubingen, Germany
- Founders Lars Zender, Stefan Laufer, Wolfgang Albrecht
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website heparegenix.com
- Social LinkedIn
- Legal Name Heparegenix Gmbh
- Total Equity Funding$62.15M (USD)
in 4 rounds
- Latest Funding Round$24.34M (USD), Series C
Apr 2025
- InvestorsAscenion
& 7 more
Products & Services of HepaRegeniX
HepaRegeniX offers a comprehensive portfolio of products and services, including HRX-215.
Advances liver regeneration for acute and chronic diseases
Funding Insights of HepaRegeniX
HepaRegeniX has successfully raised a total of $62.15M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $24.34 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $62.15M
- Total Rounds 4
- Last Round Series C — $24.34M
- First Round $9.39M
(Jan 2017)
- Investors Count 8
All 4 funding rounds of HepaRegeniX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $24.34M | Series C | – | – | |
| Jul 2024 | $16.23M | Series C | – | Vesalius Biocapital | |
| Jan 2020 | $12.2M | Series B | – | Boehringer Ingelheim Venture Fund, Novo Holdings | – |
| Jan 2017 | $9.39M | Series A | – | Boehringer Ingelheim Venture Fund, Novoseeds | – |
8 investors in total: 8 institutional.
Investors in HepaRegeniX
HepaRegeniX has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Ascenion, Novoseeds and Wellington Partners Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in early-stage healthcare startups. | wellington-partners.com | Munich, Germany | ||
A European life sciences venture capital investor is operated. | vesaliusbiocapital-4.com | Contern, Luxembourg | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund. | boehringer-ingelheim-venture.com | |||
Early-stage investments are made in high-tech startups by HTGF. | htgf.de | Bonn, Germany | ||
Venture capital funding for young German technology companies. | coparion.vc | |||
Venture capital funding is provided to life science research startups. | 2001 | ascenion.de | Munich, Germany | |
Produces and supplies high-quality hybrid seeds for agricultural applications. | 2016 | novoseeds.co | Bengaluru, India |
Investor details for HepaRegeniX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HepaRegeniX
4 people are tracked at HepaRegeniX (4 in leadership).
| Name | Role | Group |
|---|---|---|
Lars Zender | Co-Founder | Leadership |
Stefan Laufer | Co-Founder | Leadership |
Wolfgang Albrecht | Co-Founder & Managing Director | Leadership |
Birgit Jung | Managing Director | Leadership |
Complete people profiles for HepaRegeniX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of HepaRegeniX
3 dated milestones of HepaRegeniX across 8 years, from founding to its latest funding, stage changes and deals.
- Founded HepaRegeniX is founded.
- Funding First funding round of $9.4M.
- Funding Latest funding round, Series C, of $24.3M.
Web traffic of HepaRegeniX
Websites that share an audience with HepaRegeniX (heparegenix.com).
Websites whose visitors overlap most with HepaRegeniX. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hain-lifescience.de | 100% | 1.3K | #11,338,085 | View details | |
| microcollections.de | 98% | View details | |||
cat-online.com | cat-online.com | 98% | #11,695,730 | – | |
h-net.com | h-net.com | 96% | – | ||
stria.tech | stria.tech | 93% | #10,720,048 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for HepaRegeniX
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Heparegenix
Complete news archive for HepaRegeniX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HepaRegeniX
HepaRegeniX was founded in 2017.
HepaRegeniX is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.
HepaRegeniX is a funded company, having raised a total of $62.15M across 4 funding rounds to date. The company's 1st funding round was a Series A of $9.39M, raised on Jan 2017.
HepaRegeniX was founded in 2017 in Tubingen, Germany, and operates in the biotechnology sector. Small molecule therapeutics are developed by the company, with a focus on inhibitors of Mitogen-Activated Protein Kinase Kinase 4 (MKK4). This target regulates liver regeneration, enabling hepatocyte recovery in acute and chronic liver conditions. Leadership includes co-founders Lars Zender, Stefan Laufer, and Wolfgang Albrecht, alongside Managing Director Birgit Jung.
HepaRegeniX offers HRX-215.
HepaRegeniX has 8 investors. Key investors include Ascenion, Novoseeds, Wellington Partners Venture Capital, Vesalius Biocapital IV, and Novo Holdings.
HepaRegeniX operates through Heparegenix Gmbh.